true
The Precision Blog
100% sourced from leading minds on the front lines of research
All articles
-
Read: Case Study: Managing Complexity in an Autologous Cell Therapy Trial
-
Read: How Investigator Engagement Builds Enrollment Momentum 
How Investigator Engagement Builds Enrollment Momentum
-
Read: Case Study: Nectin 4 Biomarker Testing for Oncology Clinical Programs 
Case Study: Nectin 4 Biomarker Testing for Oncology Clinical Programs
-
Read: Has the rest of the world finally caught up with Latin America? 
Has the rest of the world finally caught up with Latin America?
-
Read: Case Study: Rapid Execution of Assay Validation Rescued Global Study 
Case Study: Rapid Execution of Assay Validation Rescued Global Study
-
-
Read: Clinical AI at Scale: Why Trust Matters More Than Speed 
Clinical AI at Scale: Why Trust Matters More Than Speed
-
-
Read: Hidden Strategic Edge in Clinical Trials: Financial Project Management 
Hidden Strategic Edge in Clinical Trials: Financial Project Management
-
Read: Why Most Early Autoimmune Trials Fail to Yield Decision-ready Evidence 
Why Most Early Autoimmune Trials Fail to Yield Decision-ready Evidence
-
Read: Why Global Oncology Evidence May Not Support U.S. Regulatory Approval 
Why Global Oncology Evidence May Not Support U.S. Regulatory Approval
-
Read: Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors 
Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors
-
Read: Receptor Occupancy in the Era of Multispecific Therapeutics 
Receptor Occupancy in the Era of Multispecific Therapeutics
-
-
Read: Case Study: Prescreening Intel Restores Phase 3 Colorectal Enrollment 
Case Study: Prescreening Intel Restores Phase 3 Colorectal Enrollment
-
Read: Case Study: Theranostic Radiopharm Trial and Evolving FDA Expectations 
Case Study: Theranostic Radiopharm Trial and Evolving FDA Expectations
-
-
Read: Why APAC Is Becoming a Design Decision 
Why APAC Is Becoming a Design Decision
-
-
Read: Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions 
Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions
-
-
Read: Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies 
Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies
-
Read: Case Study: Advancing IHC Assays from RUO to Clinical Trials and CDx 
Case Study: Advancing IHC Assays from RUO to Clinical Trials and CDx
-
-
Read: China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches 
China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches
-
Read: Bringing Early Phase Oncology Closer to Patients in Los Angeles 
Bringing Early Phase Oncology Closer to Patients in Los Angeles
-
Read: Radiopharmaceutical Clinical Trials: What Sponsors Need to Know About Selecting a CRO 
Radiopharmaceutical Clinical Trials: What Sponsors Need to Know About Selecting a CRO
-
-
Read: Cancer Is the Enemy: How Phase I Oncology Teams Accelerate Drug Development 
Cancer Is the Enemy: How Phase I Oncology Teams Accelerate Drug Development
-
Read: Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan 
Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan
-
-
Read: Strategic Management of Radiopharmaceutical Trial Complexity 
Strategic Management of Radiopharmaceutical Trial Complexity
-
Read: Case Study: How Monitoring Caught a Silent PK Crisis in a CAR T Rescue 
Case Study: How Monitoring Caught a Silent PK Crisis in a CAR T Rescue
-
Read: What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs 
What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs
-
-
Read: Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market 
Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market
-
-
Read: Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research 
Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research
-
Read: The Collaborative CRO Partnership Model: Amplifying Your Team 
The Collaborative CRO Partnership Model: Amplifying Your Team
-
Read: EMA PRIME Scheme Explained: Eligibility, Benefits, Risks, and When to Apply 
EMA PRIME Scheme Explained: Eligibility, Benefits, Risks, and When to Apply
-
-
Read: Case Study: Swift Stabilization in Phase 1 Solid Tumor Rescue 
Case Study: Swift Stabilization in Phase 1 Solid Tumor Rescue
-
-
Read: The EU Biotech Act: What Sponsors Need to Know About Europe's Biotechnology Transformation 
The EU Biotech Act: What Sponsors Need to Know About Europe's Biotechnology Transformation
-
Read: Navigating Complexity: Rescuing a Biomarker-Driven Breast Cancer Trial 
Navigating Complexity: Rescuing a Biomarker-Driven Breast Cancer Trial
-
Read: Hope Through Access: Inside the Partnership Bringing Novel Cancer Therapies to Patients Worldwide 
Hope Through Access: Inside the Partnership Bringing Novel Cancer Therapies to Patients Worldwide
-
Read: How a Biometrics Partnership Scaled: Stats-Only to Integrated Delivery 
How a Biometrics Partnership Scaled: Stats-Only to Integrated Delivery
-
-
Read: Case Study: Delivering Pivotal Data in Phase 3 R/R Multiple Myeloma 
Case Study: Delivering Pivotal Data in Phase 3 R/R Multiple Myeloma
-
Read: Case Study: Precise Data Management in Rare Liver Disease RNAi Trial 
Case Study: Precise Data Management in Rare Liver Disease RNAi Trial
-
Read: Phase 2-3 SCLC Case Study: Strategic Site Selection Drove Recruitment 
Phase 2-3 SCLC Case Study: Strategic Site Selection Drove Recruitment
-
Read: MHRA's International Recognition Procedure: Fast-Track Access to the UK Market 
MHRA's International Recognition Procedure: Fast-Track Access to the UK Market
-
-
Read: New Zealand Clinical Trial Landscape: Speed, Quality & Savings Explained 
New Zealand Clinical Trial Landscape: Speed, Quality & Savings Explained
-
-
Read: Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data 
Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data
-
Read: Reflect on 20 Years of Cancer Research with MIRROR Biospecimens 
Reflect on 20 Years of Cancer Research with MIRROR Biospecimens
-
Read: Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity 
Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity
-
-
Read: Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket 
Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket
-
Read: Investor Relations, Clinical Operations, and the Future of Biotech Financing 
Investor Relations, Clinical Operations, and the Future of Biotech Financing
-
-
Read: Clinical Trial Trends: Gene Therapy 
Clinical Trial Trends: Gene Therapy
-
Read: Singapore Clinical Trials: A Fast, Efficient Hub for APAC Research 
Singapore Clinical Trials: A Fast, Efficient Hub for APAC Research
-
-
Read: Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting 
Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting
-
Read: Case Study: Global Phase 1-2 TCR Therapy in Advanced Solid Tumors 
Case Study: Global Phase 1-2 TCR Therapy in Advanced Solid Tumors
-
Read: The Immune System's Secret Language: Unlocking Cellular Communication 
The Immune System's Secret Language: Unlocking Cellular Communication
-
Read: Case Study: Phase 3 Ultra-Rare Pediatric Trial in Classic Galactosemia 
Case Study: Phase 3 Ultra-Rare Pediatric Trial in Classic Galactosemia
-
Read: Case Study: Rescue of a Global Phase 3 Trial in Multiple Myeloma 
Case Study: Rescue of a Global Phase 3 Trial in Multiple Myeloma
-
Read: FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know 
FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know
-
-
Read: How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development 
How AI & Biomarkers Are Reshaping the Next Frontier in Drug Development
-
Read: Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy 
Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy
-
Read: Mining for Gold? Prospecting Biospecimen Collections to Power Precision Medicine 
Mining for Gold? Prospecting Biospecimen Collections to Power Precision Medicine
-
Read: Case Study: Early Genotype Confirmation Rescued a Phase 1-2 SCID Trial 
Case Study: Early Genotype Confirmation Rescued a Phase 1-2 SCID Trial
-
Read: Phase 3 Prostate Cancer Case Study: Radiopharm Imaging at Scale 
Phase 3 Prostate Cancer Case Study: Radiopharm Imaging at Scale
-
Read: Taiwan’s Clinical Trial Landscape: Fast, Efficient, and High-Quality Research 
Taiwan’s Clinical Trial Landscape: Fast, Efficient, and High-Quality Research
-
-
Read: From Bench to Breakthrough: How Custom Kitting Fuels Precision Trials 
From Bench to Breakthrough: How Custom Kitting Fuels Precision Trials
-
-
Read: Global Phase 1–2 ROS1 Inhibitor Case Study in NSCLC: Precision’s Path to Zero Data Issues Across 60+ Sites 
Global Phase 1–2 ROS1 Inhibitor Case Study in NSCLC: Precision’s Path to Zero Data Issues Across 60+ Sites
-
Read: Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss 
Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss
-
Read: Phase 1 Clinical Trial Designs Explained: BOIN, CRM, BLRM & Modern Adaptive Strategies 
Phase 1 Clinical Trial Designs Explained: BOIN, CRM, BLRM & Modern Adaptive Strategies
-
Read: Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM) 
Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)
-
Read: Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM) 
Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)
-
Read: Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial 
Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial
-
-
Read: Four Critical Questions to Ask Before Signing with a ‘Big Five’ CRO 
Four Critical Questions to Ask Before Signing with a ‘Big Five’ CRO
-
Read: Defaulting to a Big Five CRO? Here’s What Sponsors Wish They Knew First 
Defaulting to a Big Five CRO? Here’s What Sponsors Wish They Knew First
-
Read: Key Strategies for Future-Proofing Gene Therapy Assays 
Key Strategies for Future-Proofing Gene Therapy Assays
-
-
Read: Study Start-Up vs Site Start-Up in Clinical Research: Understanding Modern Trial Dynamics 
Study Start-Up vs Site Start-Up in Clinical Research: Understanding Modern Trial Dynamics
-
Read: Clinical Trial Site Selection: Key Challenges & Solutions for Phase 3 Success .jpg?width=396&height=224&name=7%20Common%20Phase%203%20Clinical%20Trial%20Site%20Selection%20Challenges%20(And%20How%20to%20Solve%20Them).jpg)
Clinical Trial Site Selection: Key Challenges & Solutions for Phase 3 Success
-
Read: FDA's Vision for Multiregional Clinical Trials in Oncology 
FDA's Vision for Multiregional Clinical Trials in Oncology
-
Read: Contract Research Organization vs Clinical Research Organization (CRO vs CRO) 
Contract Research Organization vs Clinical Research Organization (CRO vs CRO)
-
Read: The Amendment Trap: Why 76% of Clinical Trials Face Six-Figure Protocol Changes 
The Amendment Trap: Why 76% of Clinical Trials Face Six-Figure Protocol Changes
-
Read: Best Practices to Streamline Development of Safety Update Reports (DSURs) .png?width=396&height=224&name=Best%20Practices%20to%20Streamline%20Development%20of%20Safety%20Update%20Reports%20(DSURs).png)
Best Practices to Streamline Development of Safety Update Reports (DSURs)
-
Read: Webinar Insights: Optimizing Cohort Management in Early-Phase Oncology Trials 
Webinar Insights: Optimizing Cohort Management in Early-Phase Oncology Trials
-
-
Read: Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership 
Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership
-
Read: 2025 Biotech Economics: CROs, Advanced Therapies & Trends in Funding 
2025 Biotech Economics: CROs, Advanced Therapies & Trends in Funding
-
Read: FDA's Project Optimus: What Pharma and Biotech Need to Know 
FDA's Project Optimus: What Pharma and Biotech Need to Know
-
Read: Case Study: Concurrent Phase 1 Solid Tumor Drug Development Successes 
Case Study: Concurrent Phase 1 Solid Tumor Drug Development Successes
-
-
Read: Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI 
Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI
-
Read: Impact of US Tariffs on Biopharmaceutical Industry 
Impact of US Tariffs on Biopharmaceutical Industry
-
Read: Case Study Phase 3 NSCLC: Site Relationships Streamline Feasibility 
Case Study Phase 3 NSCLC: Site Relationships Streamline Feasibility
-
Read: Source Data Verification Types, Trends, and Tips 
Source Data Verification Types, Trends, and Tips
-
Read: How to launch a clinical trial in South Korea: Investigational New Drug Application Process 
How to launch a clinical trial in South Korea: Investigational New Drug Application Process
-
-
Read: Advancing Diversity in Oncology Clinical Trials: 5 Key Insights from Clinical Trial Sites 
Advancing Diversity in Oncology Clinical Trials: 5 Key Insights from Clinical Trial Sites
-
-
Read: Top Functional Service Providers (FSPs) in Clinical Research for 2026 
Top Functional Service Providers (FSPs) in Clinical Research for 2026
-
Read: Clinical Trial Trends: Non-malignant Hematology 
Clinical Trial Trends: Non-malignant Hematology
-
Read: Gene Therapy Assays: Regulatory Compliance with Unified Immunogenicity 
Gene Therapy Assays: Regulatory Compliance with Unified Immunogenicity
-
-
Read: Top Clinical Research Organizations for Rare Diseases in 2025 
Top Clinical Research Organizations for Rare Diseases in 2025
-
Read: Clinical Trial Trends: Late Phase Oncology 
Clinical Trial Trends: Late Phase Oncology
-
Read: Clinical Trial Trends: Antibody-Drug Conjugates 
Clinical Trial Trends: Antibody-Drug Conjugates
-
Read: The BIOSECURE Act’s Impact May Outlive the Bill Itself 
The BIOSECURE Act’s Impact May Outlive the Bill Itself
-
Read: Clinical Trial Trends: Early Phase Rare Oncology 
Clinical Trial Trends: Early Phase Rare Oncology
-
Read: Custom FSP Models That Help Biotechs Scale Smarter 
Custom FSP Models That Help Biotechs Scale Smarter
-
Read: Chevron Deference: A New Era for Biotech 
Chevron Deference: A New Era for Biotech
-
Read: Protocol Study Design: Bridging Clinical Goals with Patient Needs 
Protocol Study Design: Bridging Clinical Goals with Patient Needs
-
Read: Optimizing Immunohistochemistry Validation and Regulatory Strategies 
Optimizing Immunohistochemistry Validation and Regulatory Strategies
-
-
Read: Expediting Clinical Trial Study Start-up in Australia 
Expediting Clinical Trial Study Start-up in Australia
-
Read: Rescuing a Complex Hematology Oncology Trial: Case Study in Precision 
Rescuing a Complex Hematology Oncology Trial: Case Study in Precision
-
-
Read: Lean Authoring: Bringing Efficiency and Speed to Clinical Study Reports 
Lean Authoring: Bringing Efficiency and Speed to Clinical Study Reports
-
Read: What Is an FDA Breakthrough Therapy Designation? 
What Is an FDA Breakthrough Therapy Designation?
-
Read: Women Leaders Share Raw Truths About Leadership in Life Sciences 
Women Leaders Share Raw Truths About Leadership in Life Sciences
-
-
Read: Challenges & Opportunities in Cell and Gene Therapy 
Challenges & Opportunities in Cell and Gene Therapy
-
Read: How European Oncology Site Networks Streamline Clinical Trial Site Selection 
How European Oncology Site Networks Streamline Clinical Trial Site Selection
-
Read: Clinical Trial Trends: Early Phase Oncology 
Clinical Trial Trends: Early Phase Oncology
-
Read: The Dose Dilemma: Lessons from Sotorasib and the Future of Oncology Drug Optimization 
The Dose Dilemma: Lessons from Sotorasib and the Future of Oncology Drug Optimization
-
Read: Why Antibody-Drug Conjugates Are Revolutionizing Precision Oncology 
Why Antibody-Drug Conjugates Are Revolutionizing Precision Oncology
-
Read: Therapeutic Genome Editing – Reshaping the Landscape of Advanced Therapies 
Therapeutic Genome Editing – Reshaping the Landscape of Advanced Therapies
-
Read: Clinical Trial Trends: Non-Hodgkin’s Lymphoma 
Clinical Trial Trends: Non-Hodgkin’s Lymphoma
-
Read: US Crackdown on Chinese Clinical Trials: What’s at Stake for Biopharma? 
US Crackdown on Chinese Clinical Trials: What’s at Stake for Biopharma?
-
Read: Safety isn’t a Milestone but a Mindset in Clinical Research 
Safety isn’t a Milestone but a Mindset in Clinical Research
-
Read: Will BIOSECURE Boost US Pharma? 
Will BIOSECURE Boost US Pharma?
-
Read: Advancing Equity in Clinical Trials: Unpacking the FDA’s Diversity Guidance 
Advancing Equity in Clinical Trials: Unpacking the FDA’s Diversity Guidance
-
-
Read: Case Study: Effective Management of a Rescue Study 
Case Study: Effective Management of a Rescue Study
-
Read: Case Study: A Double Rescue in Advanced Solid Tumor Clinical Trials 
Case Study: A Double Rescue in Advanced Solid Tumor Clinical Trials
-
-
Read: How South Korea Became a Leading Destination for Clinical Trials 
How South Korea Became a Leading Destination for Clinical Trials
-
Read: Immunohistochemistry in Precision Medicine: From Biomarker to Clinical Trial Assay 
Immunohistochemistry in Precision Medicine: From Biomarker to Clinical Trial Assay
-
-
Read: The Bottom Line on Chevron's Overturn 
The Bottom Line on Chevron's Overturn
-
Read: Clinical Trial Trends: Multiple Myeloma 
Clinical Trial Trends: Multiple Myeloma
-
Read: Clinical Trial Trends: Rare Oncology vs Non-Oncology 
Clinical Trial Trends: Rare Oncology vs Non-Oncology
-
Read: AI's Role in Reshaping Drug Development: FDA Workshop Recap 
AI's Role in Reshaping Drug Development: FDA Workshop Recap
-
Read: Clinical Trial Trends: Ovarian Cancer 
Clinical Trial Trends: Ovarian Cancer
-
Read: Lessons Learned from a Rare Pediatric Case Study 
Lessons Learned from a Rare Pediatric Case Study
-
Read: Inside a CRO: Operational Strategy and Excellence 
Inside a CRO: Operational Strategy and Excellence
-
Read: FDA Approves Breakthrough Cell Therapy for Synovial Sarcoma 
FDA Approves Breakthrough Cell Therapy for Synovial Sarcoma
-
Read: FDA ODAC Vote: Key Changes for Perioperative Cancer Trials 
FDA ODAC Vote: Key Changes for Perioperative Cancer Trials
-
Read: Top Clinical Research Organizations for Oncology in 2024 
Top Clinical Research Organizations for Oncology in 2024
-
Read: Perspectives on the Future of the BIOSECURE Act 
Perspectives on the Future of the BIOSECURE Act
-
Read: Bracing for Impact of BIOSECURE Act 
Bracing for Impact of BIOSECURE Act
-
Read: Clinical Trial Trends: Rare Cardiovascular 
Clinical Trial Trends: Rare Cardiovascular
-
Read: Clinical Trial Trends: Rare Autoimmune 
Clinical Trial Trends: Rare Autoimmune
-
Read: Clinical Trial Trends: Rare Oncology 
Clinical Trial Trends: Rare Oncology
-
Read: Clinical Trial Trends: Rare Metabolic 
Clinical Trial Trends: Rare Metabolic
-
Read: Clinical Trial Trends: Radiopharmaceuticals 
Clinical Trial Trends: Radiopharmaceuticals
-
Read: Clinical Trial Trends: Rare Pediatric 
Clinical Trial Trends: Rare Pediatric
-
Read: Protein Assays: Choosing the Most Effective Method for Biopharmaceutical Development 
Protein Assays: Choosing the Most Effective Method for Biopharmaceutical Development
-
-
Read: Clinical Trial Trends: Rare CNS 
Clinical Trial Trends: Rare CNS
-
Read: Case Study: Streamlining Radiopharmaceutical Clinical Trials .png?width=396&height=224&name=Streamlining%20Radiopharmaceutical%20Clinical%20Trials%20Precision%20Case%20Study%20(2).png)
Case Study: Streamlining Radiopharmaceutical Clinical Trials
-
Read: Navigating Site Activation Strategy Under the EU Clinical Trials Regulation 
Navigating Site Activation Strategy Under the EU Clinical Trials Regulation
-
-
Read: Considerations for Your Pre-IND Meeting With the FDA 
Considerations for Your Pre-IND Meeting With the FDA
-
Read: Precision Medicine in Pediatrics: Biomarkers and Assay Development 
Precision Medicine in Pediatrics: Biomarkers and Assay Development
-
Read: FDA Draft Guidance Encourages Broader Inclusion Criteria in Oncology Trials 
FDA Draft Guidance Encourages Broader Inclusion Criteria in Oncology Trials
-
Read: When Should Biopharma Companies Buy, Partner or Develop Innovative Assets? .jpg?width=396&height=224&name=Biospace%20-%20Biopharma%20Companies%20Buy_%20Partner%20or%20Develop%20(1).jpg)
When Should Biopharma Companies Buy, Partner or Develop Innovative Assets?
-
-
Read: Strategic Portfolio Management in Cell and Gene Therapy: Keys to Growth and Impact 
Strategic Portfolio Management in Cell and Gene Therapy: Keys to Growth and Impact
-
You've reach the end
